On Nov 14, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $150 to $185.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $132 to $176.
Goldman Sachs analyst Matthew Sykes maintains with a buy rating, and adjusts the target price from $140 to $160.
Jefferies analyst Tycho Peterson maintains with a buy rating, and adjusts the target price from $142 to $182.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and maintains the target price at $175.
BTIG analyst Mark Massaro maintains with a buy rating, and adjusts the target price from $150 to $185.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The reassessment of estimates for Natera, taking into account the Q3 results along with the revised outlook for 2024 and preliminary commentary on 2025 from the management discussion, supports the view that the stock's significant multiple is well warranted. This is due to several factors that are expected to contribute to both near-term and long-term upside in estimates, positioning the stock as a high-conviction selection.
Natera delivered another robust quarterly performance, according to an analyst. The company is achieving impressive results across various business aspects, such as volume, selling price, margin, and cash burn, with potential for continued enhancement through 2025. The company is considered one of the premier entities within the diagnostics sector.
Natera's Q3 results were exceptionally strong, as evidenced by the continuous improvement in its fundamentals. The company is channeling its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
Natera recorded an impressive quarter with sales, margins, and cash flow that significantly exceeded expectations.
Natera's third quarter revenue and gross margins exceeded estimates, signaling a robust business momentum. This includes a significant 60% year-over-year growth in Signatera clinical volume and noteworthy gains in the women's health sector.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月14日，多家华尔街大行更新了$Natera (NTRA.US)$的评级，目标价介于150美元至185美元。
摩根士丹利分析师Tejas Savant维持买入评级，并将目标价从132美元上调至176美元。
高盛集团分析师Matthew Sykes维持买入评级，并将目标价从140美元上调至160美元。
富瑞集团分析师Tycho Peterson维持买入评级，并将目标价从142美元上调至182美元。
TD Cowen分析师Daniel Brennan维持买入评级，维持目标价175美元。
BTIG分析师Mark Massaro维持买入评级，并将目标价从150美元上调至185美元。
此外，综合报道，$Natera (NTRA.US)$近期主要分析师观点如下：
对natera的估算进行重新评估，考虑到第三季度的结果以及对2024年的修订展望和管理讨论中对2025年的初步评论，支持该股票显著的市盈率是合理的观点。这是由于多种因素预期将有助于估算的短期和长期上行，使该股票成为高信念的选择。
分析师表示，natera在又一个季度里实现了强劲的表现。该公司在成交量、销售价格、利润率和现金消耗等各个业务领域取得了令人瞩目的成绩，并有潜力在2025年继续提升。该公司被认为是诊断板块内的顶尖实体之一。
natera的第三季度结果非常强劲，基础指标持续改善。该公司将运营现金流重新投入到业务中，这增强了其在销售、市场营销、医疗事务和法律方面的地位。
natera在一个季度中记录了令人印象深刻的销售、利润率和现金流，显著超出预期。
natera的第三季度营业收入和毛利率超出预期，标志着强劲的业务势头。这包括Signatera临床成交量同比增长60%以及女性健康板块的显著增长。
以下为今日8位分析师对$Natera (NTRA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
